Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium-Reference-Cited by-同舟云学术

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

Published:2014-11-19 Issue:6 Volume:121 Page:876-882
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Jabbour Elias J.¹,Garcia-Manero Guillermo¹,Strati Paolo¹,Mishra Asmita²,Al Ali Najla H.³,Padron Eric²,Lancet Jeffrey²,Kadia Tapan¹,Daver Naval¹,O'Brien Susan¹,Steensma David P.⁴,Sekeres Mikkael A.⁵,Gore Steven D.⁶,Dezern Amy⁷,Roboz Gail J.⁸,List Alan F.²,Kantarjian Hagop M.¹,Komrokji Rami S.²

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Medical Oncology; H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

3. Department of Malignant Hematology; H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

4. Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

5. Department of Hematology and Oncology; Cleveland Clinic Main Campus; Cleveland Ohio

6. Department of Hematology; Yale School of Medicine; New Haven Connecticut

7. Department of Oncology; Johns Hopkins University; Baltimore Maryland

8. Department of Hematology; Cornell University; New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29145/fullpdf

Reference21 articles.

1. Myelodysplastic syndromes;Tefferi;N Engl J Med,2009

2. Unraveling the molecular pathophysiology of myelodysplastic syndromes;Bejar;J Clin Oncol,2011

3. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

4. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B;Silverman;J Clin Oncol,2002

5. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome;Blood Advances;2024-08-13

2. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

3. Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives;Cancers;2024-04-15

4. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

5. Myelodysplastic syndrome: A challenging entity;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024